ISOPAQUE 440
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISOPAQUE 440 is an injectable diagnostic agent approved in 1973 by GE HealthCare. The specific mechanism of action and therapeutic indications are not publicly detailed in available data, but the injectable formulation suggests use as a contrast or diagnostic imaging agent. Patient population and clinical utility depend on undisclosed indication.
LOE Approaching
Product is nearing loss of exclusivity with no linked job openings, indicating a mature franchise with minimal active commercial investment or team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a legacy product with minimal hiring activity. Career opportunities are limited to defensive commercial roles focused on margin protection and managed decline rather than growth initiatives.
Brand ManagerProduct Manager
Worked on ISOPAQUE 440 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.